· 个股论点
涉及标的： $CIFR$CORZ$CRWV$IREN$META$NBIS
对于 $CRWV 而言，问题在于其收购 $CORZ 未能获批。Core Scientific 本应比那 90 亿美元的收购价带来更大价值。若能在其现有合同基础上，通过收购为全栈模型（Full Stack Model）增加更多 GW 级算力，将是极度看涨（omega bullish）的利好。 Coreweave 每年还有超过 10 亿美元的利息债务，这对自由现金流（FCF）和利润率造成了极大拖累（相比之下，$NBIS、$CIFR、$IREN 使用的是可转换票据）。 $NBIS 已经实现了 $CRWV 的全栈垂直整合，但拥有更高的利用率、更好的编排/性能（根据其白皮书）、无巨额债务利息以及高积压订单，因此市场看到了其他风险更低、上行空间更大的替代方案。 不过，如果 $CRWV 获得美国政府合同批准，那将是另一个巨大的看涨催化剂。但我们已经看到像与 $META 签订的 140 亿美元这样的大型合同积压订单，然而其债务利息确实荒谬。
For $CRWV it was $CORZ acquisition failing to get approved. Core scientific would have delivered so much more value than that 9B price tag. Having more GW capacity added to their full stack model (on top of their existing contract with them), would have been omega bullish with the acquisition. Coreweave also has $1B+ in interest debt a year, which is an extremely big drag on FCF + margins (compared to $NBIS, $CIFR, $IREN with did convertible notes). $NBIS already achieved what $CRWV did with full-stack vertical integration, but higher utilization + better orchestration/performance (as per their whitepaper) + no massive interest on debt + high backlogs, so markets see other lower risk, higher upside, alternatives emerging. If $CRWV get approved for US Gov contracts though, that would be another huge catalyst upside. But we already have visibility into large contracted backlogs like $14B with $META but the debt interest is just ridiculous.